Grail’s Galleri Cancer Test Faces Landmark FDA Review After Mixed Clinical Results
Grail’s ambitious effort to transform cancer screening is approaching a pivotal regulatory moment. The U.S. Food and Drug Administration has scheduled an advisory committee meeting for September 23, 2026, to evaluate the company’s Galleri multi-cancer early detection blood test. It will be the first FDA advisory panel convened to consider a premarket approval application for […]
FDA Unexpectedly Rejects Promising Cancer Therapy Over Manufacturing Concerns
The U.S. Food and Drug Administration has unexpectedly rejected ITM-11, an experimental radiopharmaceutical developed by Germany’s ITM Isotope Technologies Munich for patients with gastroenteropancreatic neuroendocrine tumors, or GEP-NETs. The decision represents a significant setback for ITM and delays the arrival of a treatment expected to become an important competitor to Novartis’ established radiopharmaceutical therapy Lutathera. […]
Rare Childhood Cancer Cases Raise Alarm in Southern California Community
Families in Ladera Ranch, an affluent suburban community in southern California, are demanding an urgent investigation after six local children were diagnosed with Ewing sarcoma, an exceptionally rare cancer affecting bones and surrounding soft tissue. The cases have generated widespread fear among residents and prompted local and federal officials to request a comprehensive scientific review […]
